Loading...
Indication – Melanoma/Skin cancer2024-06-04T09:57:37+01:00

Melanoma/Skin Cancer

Emerging therapies in solid tumors

December 9th, 2022|

Interleukin-8 (IL-8), also known as chemokine (C-X-C motif) ligand 8, is a pro-inflammatory chemokine that ­exerts direct pro-tumorigenic effects ­primarily by recruiting immunosuppressive cells into the tumor microenvironment such as neutrophils and myeloid-derived suppressor cells. IL-8 has also been shown to promote cancer progression and resistance to therapy, by inducing angiogenesis, epithelial-mesenchymal transition (EMT), and cancer stem cell (CSC) self-renewal.

Novel early clinical approaches in solid tumors

September 13th, 2022|

Chimeric antigen receptor (CAR)-T cells have proven to be effective in the clinic for patients with malignant B-cell tumors but their application for solid tumors is challenging. BNT211 is a novel therapeutic approach which comprises two components: CAR-T cells targeting the Claudin 6 (CLDN6) and a CLDN6-encoding CAR-T cell amplifying RNA vaccine (CARVac).

Checkpoint inhibition: predictors, resistance and immunogenomic features

June 8th, 2021|

Immune checkpoints, such as cytotoxic T-lymphocyte associated protein-4 (CTLA-4) or programmed cell death protein 1 (PD-1), downregulate T-cell responses and are crucial for self-tolerance, which protects the body against attacking cells indiscriminately. Tumor cells hijack this mechanism to evade the immune system through the activation of immune checkpoints and inhibition of the T-cell response.

Go to Top